Five things for pharma marketers to know: Wednesday, July 6, 2016

1. Pfizer said it will disclose in promotional materials that opioid painkillers carry a risk of addiction, a move that officials hope will be replicated at other makers of painkillers. Pfizer had been sued along with four other manufacturers by the city of Chicago over allegations that they illegally marketed opioids. (WaPo)

2. Medivation opened talks with Sanofi and other suitors for a possible acquisition, just months after refusing a deal, sources told The Wall Street Journal. The drugmaker has a market value of about $10 billion. (WSJ)

3. Almirall, a Spanish drugmaker, may be interested in buying the dermatology assets from Valeant Pharmaceuticals. Valeant is considering selling some of its assets to reduce its debt. (Reuters)

4. Commercial institutional review boards now oversee about 70% of clinicals trials in the U.S. Drugmakers have encouraged researchers to use commercial boards rather than nonprofit ones. (Stat)

5. ICYMI: Five of the fastest growing advertising spenders in 2015 are drugmakers. Spending by Novo Nordisk, one of the fastest growing spenders, rose 195% to $261 million last year. (Ad Age)